MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Frontiers | The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma | Cell and Developmental Biology
An overview of the c-MET signaling pathway | Semantic Scholar
c-Met Proto-oncogene | Targeting Overexpression
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET receptor inhibition - ppt download
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | PNAS
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
c-MET receptor tyrosine kinase as a molecular target in advanced hepat | JHC
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
c-MET amplification upregulated PD-L1 expression in EGFR-TKI resistant... | Download Scientific Diagram
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas - Journal of Thoracic Oncology
Cancers | Free Full-Text | Activated HGF-c-Met Axis in Head and Neck Cancer | HTML
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
